2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1749

Targeting of CD22 by Epratuzumab Potentially Raises the Threshold of B Cell Receptor Activation
Abstract Number: 1173

Targeting Remission in Juvenile Idiopathic Arthritis in Routine Clinical Care: Experience in 175 Newly-Diagnosed Patients
Abstract Number: 2281

Tartrate-Resistant Acid Phosphatase Deficiency in the Predisposition to Systemic Lupus Erythematosus
Abstract Number: 1891

Teaching Medical Students Principles of Chronic Disease: Medicine of the 4th and 5th Dimension At Weill-Cornell
Abstract Number: 2055

TEAM-Managed Care of Biological Patients At A Canadian Centre
Abstract Number: 2053

Tele-Rheumatology: The Future Is Now
Abstract Number: 2352

Temporal Artery Biopsy Culture in Tridimensional Matrix. an in Vitro Model for Functional Studies in Giant-Cell Arteritis
Abstract Number: 1871

Tender Point Count and Pressure Pain Threshold As Predictors of Chronic Widespread Pain and Health Status in a Seven Year Prospective Study
Abstract Number: 2586

Tendon and Ligament Involvement in Gout: A Dual Energy Computed Tomography Study
Abstract Number: 788

Tenofovir, a Potent Anti-Viral Agent, Is an Ecto-5’Nucleotidase (CD73) Inhibitor That Prevents Dermal Fibrosis in a Murine Model of Scleroderma
Abstract Number: 1048

Tenosynovitis in Carpal Tunnel Syndrome – Prevalence and Comparison Between Ultrasonography, Surgery and Histology
Abstract Number: 1480

The 15% Rule in Scleroderma: A Systematic Review of the Frequency of Organ Complications in Systemic Sclerosis
Abstract Number: 1862

The 2012 Canadian Fibromyalgia Guidelines: Clinically Applicable Recommendations for the Management of Fibromyalgia
Abstract Number: 1768

The Absolute Concentration of Anti Citrullinated Protein Antibodies in Serum and Synovial Fluid in Relation to Total Immunoglobulin-Concentrations
Abstract Number: 473

The Addition of Another Disease-Modifying Anti-Rheumatic Drug to Methotrexate in Place of Infliximab Reduces the Flare Rate During 2 Years After Infliximab Discontinuation in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].